IP Library › Granted Patent US 12,636,661
Granted Patent B2
US 12,636,661 · App. 18/333,852 · Granted May 26, 2026

Blood and bone marrow fractionation devices and methods

Inventors: Michael Masters (Broomfield, CO); Christopher Centeno (Broomfield, CO); Matthew Murphy (Broomfield, CO); Matthew Cooksey (Broomfield, CO); Dustin Berger (Broomfield, CO); Neven Steinmetz (Broomfield, CO)
Assignee: REGENEXX, LLC
B04B5/0442A61M1/3693B01D21/262B04B7/04B04B11/06B04B2005/0485
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,636,661
App. No.
18/333,852
Granted
May 26, 2026
Kind
B2
Abstract

Apparatus, system, and method embodiments provide a fractionation device for the fractionation or separation of blood or bone marrow aspirate (BMA) into one or more component layers and the efficient collection of layers of interest. The fractionation device includes a generally cylindrical sidewall, a top wall connected to an upper portion of the sidewall, a bottom wall connected to a lower portion of the sidewall, and an interior partition. The interior partition includes a sloped portion contacting the sidewall and a vertical portion contacting the top wall.

Claims (85)

1 . A fractionation device comprising:

a sidewall, the sidewall having a generally cylindrical profile;

a top wall connected to an upper portion of the sidewall;

a bottom wall connected to a lower portion of the sidewall;

an interior partition comprising:

a sloped portion contacting the sidewall; and

a vertical portion contacting the top wall;

an upper chamber defined within the fractionation device by the interior partition, the top wall, and the upper portion of the sidewall;

a lower chamber defined within the fractionation device by the interior partition, an upper plunger surface of a captive plunger engaged with the sidewall, and the lower portion of the sidewall;

a lower region of the upper chamber defined by the sloped portion of the interior partition adjacent to the sidewall;

a sloped indentation formed in the sidewall, the sloped indentation defining a side of the sloped portion and causing the sloped portion to become narrower toward the lower region; and

a threaded opening formed in and through the bottom wall.

2 . The fractionation device of claim 1 further comprising:

an input channel extending from the top wall to the lower chamber; and

an overflow window at least partially formed in the vertical portion of the interior partition and providing a fluid pathway between the input channel and the upper chamber, wherein the top wall defines an upper boundary of the overflow window.

3 . The fractionation device of claim 2 , wherein the input channel is defined in part by the vertical portion of the interior partition and the upper portion of the sidewall.

4 . The fractionation device of claim 3 further comprising:

one or more input channel indentations in the sidewall at the input channel to restrict a horizontal cross section of the input channel, wherein the one or more input channel indentations curve inward into the input channel toward the vertical portion.

5 . The fractionation device of claim 3 further comprising:

a plurality of ports extending through the top wall.

6 . The fractionation device of claim 5 further comprising:

a first port of the plurality of ports opening into the input channel; and

an indentation in the sidewall causing a portion of the sidewall to extend toward the vertical portion of the interior partition within the input channel and under the first port.

7 . The fractionation device of claim 6 further comprising:

a lipid layer collection tube extending from the first port toward the lower chamber and having a length configured to extract at least a portion of the lipid layer.

8 . The fractionation device of claim 7 further comprising:

a second port of the plurality of ports opening into the upper chamber adjacent to the vertical portion of the interior partition; and

a plasma layer collection tube extending from the second port to a position within the upper chamber and having a length configured to extract at least a portion of the plasma layer.

9 . The fractionation device of claim 8 further comprising:

a third port of the plurality of ports opening into the upper chamber adjacent to the sidewall and above the lower region of the upper chamber; and

a leukocyte and platelet layer collection tube extending from the third port to a position above the lower region of the upper chamber and having a length configured to extract at least a portion of the leukocyte and platelet layer.

10 . The fractionation device of claim 1 , wherein the lower region of the upper chamber defined by the sloped portion of the interior partition adjacent to the sidewall comprises a flat portion configured to collect a platelet rich pellet layer or a leukocyte and platelet rich pellet layer, wherein the flat portion is a narrowest region of the sloped portion.

11 . The fractionation device of claim 1 , wherein the sidewall is fabricated from an optically transparent material.

12 . The fractionation device of claim 1 further comprising:

a threaded rod having threads sized to engage with the threaded opening.

13 . A method of collecting a blood or bone marrow aspirate (BMA) fraction, the method comprising:

providing a fractionation device comprising:

a sidewall, the sidewall having a generally cylindrical profile;

a top wall connected to an upper portion of the sidewall;

a bottom wall connected to a lower portion of the sidewall;

an interior partition comprising:

a sloped portion contacting the sidewall; and

a vertical portion contacting the top wall;

an upper chamber defined within the fractionation device by the interior partition, the top wall, and the upper portion of the sidewall;

a lower chamber defined within the fractionation device by the interior partition, an upper plunger surface of a captive plunger engaged with the sidewall, and the lower portion of the sidewall;

a lower region of the upper chamber defined by the sloped portion of the interior partition adjacent to the sidewall;

a sloped indentation formed in the sidewall, the sloped indentation defining a side of the sloped portion and causing the sloped portion to become narrower toward the lower region; and

a threaded opening formed in and through the bottom wall;

obtaining blood or bone marrow aspirate (BMA) from a patient;

pretreating the blood or the BMA from the patient;

inserting the blood or the BMA into the lower chamber of the fractionation device;

centrifuging the fractionation device in a first centrifuge cycle to separate the blood or the BMA into different layers;

engaging a threaded rod with the threaded opening;

rotating the threaded rod within the threaded opening to cause the captive plunger to rise within the lower chamber of the fractionation device until a plasma layer overflows into the upper chamber of the fractionation device via an overflow window formed in the vertical portion of the interior partition and providing a fluid pathway between an input channel and the upper chamber; and

removing at least a portion of the plasma layer from the upper chamber of the fractionation device.

14 . The method of claim 13 , wherein the blood or the BMA is inserted into the fractionation device via the input channel extending from the top wall to the lower chamber.

15 . The method of claim 13 , wherein, when BMA is used, the threaded rod is first rotated to cause a lipid layer to rise to a lipid layer collection tube extending from a first port toward the lower chamber, wherein the first port opens into the input channel, the method further comprising:

removing at least a portion of the lipid layer via the lipid layer collection tube from the fractionation device.

16 . The method of claim 13 , further comprising:

after rotating the threaded rod within the threaded opening to cause the captive plunger to rise within the lower chamber of the fractionation device until the plasma layer overflows into the upper chamber of the fractionation device via the overflow window, further rotating the threaded rod so that a leukocyte and platelet rich amount of red blood cells enter the upper chamber;

after rotating the threaded rod so that a leukocyte and platelet rich amount of red blood cells enter the upper chamber, removing the threaded rod from the fractionation device and centrifuging the fractionation device in a second centrifuge cycle to separate the plasma layer and the leukocyte and platelet rich amount of red blood cells into one or more layers including a leukocyte and platelet rich pellet;

removing at least the portion of the plasma layer from the upper chamber; and

removing at least a portion of the leukocyte and platelet rich pellet from the upper chamber.

17 . The method of claim 16 , wherein at least the portion of the plasma layer is removed from the upper chamber of the fractionation device via a second port opening into the upper chamber adjacent to the vertical portion of the interior partition and via a plasma layer collection tube extending from the second port to a position within the upper chamber.

18 . The method of claim 17 , wherein at least the portion of the leukocyte and platelet rich pellet is removed via a third port opening into the upper chamber adjacent to the sidewall and above the lower region of the upper chamber via a leukocyte and platelet layer collection tube extending from the third port to a position above the lower region of the upper chamber.

19 . The method of claim 18 , wherein at least the portion of the leukocyte and platelet rich pellet is collected in the lower region of the upper chamber.

20 . The method of claim 19 , wherein the lower region of the upper chamber defined by the sloped portion of the interior partition adjacent to the sidewall comprises a flat portion configured to collect the leukocyte and platelet rich pellet, and wherein at least the portion of the leukocyte and platelet rich pellet that is collected in the lower region of the upper chamber is disposed over the flat portion of the sloped portion of the interior partition.

21 . The method of claim 16 , further comprising:

providing a counterweight configured to counterbalance the fractionation device and having a first center of gravity in a first orientation and a second center of gravity in a second orientation;

wherein, during the first centrifuge cycle, the counterweight is in the first orientation and, during the second centrifuge cycle, the counterweight is in the second orientation.

22 . A system comprising:

a fractionation device comprising:

a sidewall, the sidewall having a generally cylindrical profile;

a top wall connected to an upper portion of the sidewall;

a bottom wall connected to a lower portion of the sidewall;

an interior partition comprising:

a sloped portion contacting the sidewall; and

a vertical portion contacting the top wall;

an upper chamber defined within the fractionation device by the interior partition, the top wall, and the upper portion of the sidewall;

a lower chamber defined within the fractionation device by the interior partition, an upper plunger surface of a captive plunger engaged with the sidewall, and the lower portion of the sidewall;

a lower region of the upper chamber defined by the sloped portion of the interior partition adjacent to the sidewall;

a sloped indentation formed in the sidewall, the sloped indentation defining a side of the sloped portion and causing the sloped portion to become narrower toward the lower region; and

a threaded opening formed in and through the bottom wall;

a centrifuge configured to receive the fractionation device; and

a counterweight configured to be placed in the centrifuge opposite the fractionation device to counterbalance the fractionation device and having a first center of gravity in a first orientation and a second center of gravity in a second orientation.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 7, 2023
From: MASTERS, MICHAEL; CENTENO, CHRISTOPHER; MURPHY, MATTHEW; COOKSEY, MATTHEW; BERGER, DUSTIN; STEINMETZ, NEVEN
To: REGENEXX, LLC
Reel/Frame 064182/0741 →
Continuity (1)
Related Publication 20240416363A1 · Dec 19, 2024
References Cited (125)
US 6010627A · Hood, III · 2000 [cited by applicant]
US 6398972B1 · Blasetti et al. · 2002 [cited by applicant]
US 6893412B2 · Saito et al. · 2005 [cited by applicant]
US 6905612B2 · Dorian et al. · 2005 [cited by applicant]
US 7060018B2 · Skinkle et al. · 2006 [cited by applicant]
US 7445125B2 · Ellsworth et al. · 2008 [cited by applicant]
US 7452344B2 · Jorgensen et al. · 2008 [cited by applicant]
US 7520402B2 · Ellsworth et al. · 2009 [cited by applicant]
US 7745106B2 · Beretta et al. · 2010 [cited by applicant]
US D632801S · Kyle et al. · 2011 [cited by applicant]
US 7976796B1 · Smith et al. · 2011 [cited by applicant]
US 8119013B2 · Leach et al. · 2012 [cited by applicant]
US 8133389B2 · Dorian et al. · 2012 [cited by applicant]
US 8177072B2 · Chapman et al. · 2012 [cited by applicant]
US 8348066B2 · Ellsworth · 2013 [cited by applicant]
US 8361005B2 · Arm et al. · 2013 [cited by applicant]
US 8460227B2 · Bare et al. · 2013 [cited by applicant]
US 8551344B2 · Swift et al. · 2013 [cited by applicant]
US 8696905B2 · Coull et al. · 2014 [cited by applicant]
US 8734373B2 · Esteron et al. · 2014 [cited by applicant]
US 8802362B2 · Grippi et al. · 2014 [cited by applicant]
US 8992862B2 · Leach et al. · 2015 [cited by applicant]
US 9011800B2 · Leach et al. · 2015 [cited by applicant]
US 9050403B2 · Morimoto et al. · 2015 [cited by applicant]
US 9095665B2 · Pages et al. · 2015 [cited by applicant]
US 9095798B2 · Chapman et al. · 2015 [cited by applicant]
US 9101925B2 · Chapman et al. · 2015 [cited by applicant]
US 9120095B2 · O'Connell, Jr. · 2015 [cited by applicant]
US 9138664B2 · Leach et al. · 2015 [cited by applicant]
US 9239276B2 · Landrigan et al. · 2016 [cited by applicant]
US 9259730B2 · Serhan et al. · 2016 [cited by applicant]
US 9329165B2 · Ihm et al. · 2016 [cited by applicant]
US 9393269B2 · Harris et al. · 2016 [cited by applicant]
US 9421319B2 · Hwang · 2016 [cited by applicant]
US 9535052B2 · Singh et al. · 2017 [cited by applicant]
US 9573130B2 · Hassouneh et al. · 2017 [cited by applicant]
US 9649579B2 · Leach et al. · 2017 [cited by applicant]
US 9696242B2 · Walker et al. · 2017 [cited by applicant]
US 9718003B1 · Petrie, Jr. · 2017 [cited by applicant]
US 9757506B2 · Ra et al. · 2017 [cited by applicant]
US 9775942B2 · Jeon · 2017 [cited by applicant]
US 9808568B2 · O'Connell, Jr. · 2017 [cited by applicant]
US 10040064B1 · Petrie, Jr. · 2018 [cited by applicant]
US 10214764B2 · Walsh et al. · 2019 [cited by applicant]
US 10272445B2 · Ewer · 2019 [cited by applicant]
US 10351813B2 · Johnson et al. · 2019 [cited by applicant]
US 10393728B2 · Woodell-May · 2019 [cited by applicant]
US 10518275B2 · Sengun et al. · 2019 [cited by applicant]
US 10537888B2 · Pennie · 2020 [cited by applicant]
US 10646884B2 · Nash et al. · 2020 [cited by applicant]
US 10857549B2 · Ewer · 2020 [cited by applicant]
US 10870110B2 · Olson · 2020 [cited by applicant]
US 10871427B2 · Hsu et al. · 2020 [cited by applicant]
US 10987672B2 · Pennie · 2021 [cited by applicant]
US 11065629B2 · Kessler et al. · 2021 [cited by applicant]
US 11135580B1 · Kowalewski · 2021 [cited by applicant]
US 20040167004A1 · Jorgensen et al. · 2004 [cited by applicant]
US 20040182795A1 · Dorian et al. · 2004 [cited by applicant]
US 20050109716A1 · Leach et al. · 2005 [cited by applicant]
US 20060094865A1 · Kapur · 2006 [cited by applicant]
US 20060251628A1 · Attawia · 2006 [cited by applicant]
US 20060278588A1 · Woodell-May · 2006 [cited by applicant]
US 20080199900A1 · Signore et al. · 2008 [cited by applicant]
US 20090014391A1 · Leach et al. · 2009 [cited by applicant]
US 20090221075A1 · Dorian et al. · 2009 [cited by applicant]
US 20090289014A1 · Hoeppner · 2009 [cited by applicant]
US 20100256595A1 · Leach et al. · 2010 [cited by applicant]
US 20100260721A1 · Mcgonaigie · 2010 [cited by applicant]
US 20110021334A1 · Leach · 2011 [cited by examiner]
US 20110036786A1 · Ellsworth · 2011 [cited by applicant]
US 20110284460A1 · Leach · 2011 [cited by examiner]
US 20130095007A1 · Haubert et al. · 2013 [cited by applicant]
US 20130345038A1 · Hoeppner · 2013 [cited by applicant]
US 20140054246A1 · Landrigan et al. · 2014 [cited by applicant]
US 20140205514A1 · Hwang · 2014 [cited by applicant]
US 20140356254A1 · Lee et al. · 2014 [cited by applicant]
US 20150023939A1 · Woodell-May · 2015 [cited by applicant]
US 20150104824A1 · Walker · 2015 [cited by examiner]
US 20150273360A1 · King et al. · 2015 [cited by applicant]
US 20160298076A1 · Centeno et al. · 2016 [cited by applicant]
US 20170000826A1 · Tucker · 2017 [cited by examiner]
US 20180305655A1 · Centeno et al. · 2018 [cited by applicant]
US 20180326413A1 · Walkowiak et al. · 2018 [cited by applicant]
US 20200023381A1 · Shin · 2020 [cited by applicant]
US 20200139041A1 · Zanin et al. · 2020 [cited by applicant]
US 20200246516A1 · Dorian et al. · 2020 [cited by applicant]
US 20200324285A1 · Levine et al. · 2020 [cited by applicant]
US 20210113760A1 · Heinrich · 2021 [cited by applicant]
US 20220133962A1 · Lee · 2022 [cited by applicant]
US 20240416363A1 · Masters · 2024 [cited by examiner]
CN 203724815U · 2014 [cited by applicant]
CN 108290086B · 2021 [cited by applicant]
KR 101225664B1 · 2010 [cited by applicant]
KR 20110009651A · 2011 [cited by applicant]
KR 101016166B1 · 2011 [cited by applicant]
KR 101026599B1 · 2011 [cited by applicant]
KR 101049201B1 · 2011 [cited by applicant]
KR 20110079122 · 2011 [cited by applicant]
KR 101110576B1 · 2012 [cited by applicant]
KR 101170146B1 · 2012 [cited by applicant]
KR 101277993B1 · 2013 [cited by applicant]
KR 101279652B1 · 2013 [cited by applicant]
KR 101284876B1 · 2013 [cited by applicant]
KR 200471027Y1 · 2014 [cited by applicant]
KR 101406574B1 · 2014 [cited by applicant]
KR 101433293B1 · 2014 [cited by applicant]
KR 101666451B1 · 2016 [cited by applicant]
KR 101990633B1 · 2019 [cited by applicant]
KR 102146508B1 · 2020 [cited by applicant]
KR 102223877B1 · 2021 [cited by examiner]
KR 1020230034538A · 2023 [cited by applicant]
WO WO2013066013 · 2013 [cited by applicant]
WO WO2015021189 · 2015 [cited by applicant]
WO 2016192502A1 · 2016 [cited by applicant]
WO WO2021133992 · 2021 [cited by applicant]
International Search Report and Written Opinion dated Nov. 19, 2014, for International Patent Application No. PCT/US2014/049992. [cited by applicant]
European Search Report, dated Feb. 3, 2017, 11 pages. [cited by applicant]
U.S. Appl. No. 14/778,530, Office Action-Restriction-Requirement, dated Jun. 23, 2017, 7 pages. [cited by applicant]
U.S. Appl. No. 14/778,530, Non-Final Office Action dated Sep. 13, 2017, 16 pages. [cited by applicant]
U.S. Appl. No. 14/778,530, Notice of Allowance, dated Apr. 4, 2018, 16 pages. [cited by applicant]
European Examination Report, EU Patent Application No. 14834894.9 dated Apr. 9, 2019; 4 pages. [cited by applicant]
Insausti et al., Stem Cells and Development, vol. 21, No. 2, pp. 260-272 (2012). [cited by applicant]
Notice of Allowance, U.S. Appl. No. 15/958,940, dated Sep. 30, 2019. [cited by applicant]
U.S. Appl. No. 17/569,738, Non-Final Office Action dated May 2, 2023, 20 pages. [cited by applicant]
International Search Report and Written Opinion, corresponding to PCT/US2024/029918, dated Sep. 4, 2024. [cited by applicant]